Background and Aims: Tracheobronchial pleomorphic adenoma is a rare disease which may be misdiagnosed and the proper diagnosis is usually delayed. This study is aimed to report the characteristics of tracheobronchial pleomorphic adenoma and review the relative references to enhance the knowledge of it.
Methods: A 38-year-old woman was admitted to hospital with complaint of progressive shortness of breath for 5 years. A chest CT enhanced scan revealed an endobronchial mass (oval, major axis: 1.42 cm and minor axis: 0.96 cm) located at the proximal part of the right main bronchus. Bronchoscopy identified a pink, broad-based, polypoid neoplasm with branching blood vessels on the smooth surface nearly completely obstructing the lumen of right main bronchus. The neoplasm was resected through combining an electrosurgical snare and argon plasma coagulation.
Results: Pathologic examinations showed an encapsulated biphasic lesion consisting of a mixture of epithelium and stroma with areas of hyalinization which confirmed the definite diagnosis of pleomorphic adenoma.
The recovery was good without any procedurerelated complications. The patient were free of clinical manifestations during the follow-up period for 3 years and no evidence of regenerative or residual neoplasm was found base on the follow-up chest CT enhanced scan and bronchoscopy.
Conclusion:
Tracheobronchial pleomorphic adenoma is extremely rare, thus, its incidence, aetiology and prognosis are still unclear. Most of the clinical manifestations are cough, dyspnea, wheezing and shortness of breath. To those who are suffering from airway obstruction symptoms without clear course, we should take tracheobronchial pleomorphic adenoma into consideration. Chest CT, bronchoscopy, microscopy and immunohistochemical staining can facilitate the definite diagnosis. Surgical and endoscopic resection are two major treatments. Endoscopic resection especially the combination of an electrosurgical snare and argon plasma coagulation is worthy of being promoted due to its safety and efficiency. Because of the low possibility of recurrence and potential malignant transformation, careful follow-up after resection procedure is necessary. Background and Aims: Patients with severe pulmonary emphysema suffer from disabling dyspnea, respond poorly to medical therapy, and often are unsuitable for lung volume reduction surgery. In recent years, bronchoscopic lung volume reduction approaches, including endobronchial valve/ coil placement and thermo vapour ablation techniques, have been proposed as an alternative treatment. We present our preliminary experience with BTVA of a patient with severe emphysema using Intervapour ® technology.
Methods: Our patient is a middle-aged gentleman who had COPD for the past 8 years. Lung function test showed severe obstructive pattern with significant air-trapping (FEV1 36% predicted, RV 265% predicted).
Despite optimal inhaled bronchodilator therapy, he remained symptomatic (MMRC 3) and had frequent COPD exacerbations. His chest radiograph (CXR) and computed tomography (CT) scan of the chest showed severe centrilobular upper lobe-predominant emphysema. Feasibility for BTVA was assessed based on CT analysis with Intervapor ® technology and a personalized procedure programme was proposed.
Results: The patient underwent BTVA under general anaesthesia.
A flexible bronchoscope was wedged in the anterior segment of the left upper lobe (LB3)-heated water vapour was delivered to the 3 subsegments in LB3; with a total procedural time of 30 minutes. There were no immediate post-procedural complications. He had a moderate exacerbation requiring corticosteroids 1 week after procedure. CXR 1 month post-procedure showed a mass-like consolidation over the left midzone and he was prescribed antibiotics. Repeat CXR (Figure) 3 weeks later showed complete resolution of the consolidation with residual atelectatic changes, consistent with a localized inflammatory response followed by scarring of the lung parenchyma.
Symptomatically, he improved with a COPD assessment test score improving from 25 to 14 (2 months post-procedure). He had no further exacerbations and there was a 33% reduction in his weekly use of shortacting beta-agonists. 
Conclusion

